Neha Gupta,Mohd Faiz Saifi,Kiesha Wilson et al.
Neha Gupta et al.
The incidence of venous thromboembolism (VTE) in cancer patients is 4-9 fold higher compared with the general population. The mortality rate of patients with cancer and VTE is more than 2-fold greater versus cancer patients without VTE. Giv...
WITHDRAWN: A dynamic, D-dimer-based thromboprophylaxis strategy in patients with COVID-19 [0.03%]
撤回：COVID-19患者中基于D-二聚体的动态血栓预防策略
Lantarima Bhoopat,Anastasia Martynova,April Choi et al.
Lantarima Bhoopat et al.
This article has been withdrawn at the request of the author(s). The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/polic...
Preventing venous thromboembolism for ambulatory patients with cancer: Developing the form and content of implementation strategies [0.03%]
预防癌症门诊患者发生静脉血栓栓塞症：制定实施策略的形式和内容
Karlyn A Martin,Kenzie A Cameron,Jeffrey A Linder et al.
Karlyn A Martin et al.
Background: For ambulatory cancer patients receiving systemic chemotherapy, adherence is low to recommended venous thromboembolism (VTE) prevention interventions. Previously, we identified implementation strategies to add...
COVID-19 vaccine (Ad26.COV2.S), an unlikely culprit of portal vein thrombosis in a middle-aged man [0.03%]
莫德纳新冠疫苗可能是中年男性门静脉血栓的病因
Dariusz Uczkowski,Arunabh Sekhri
Dariusz Uczkowski
While vaccination is the single most effective intervention to prevent spread of COVID-19, rare thromboembolic events have been reported following vaccination with COVID-19 vaccines ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2·S (Johnson & ...
Case Reports
Thrombosis update. 2022 Aug:8:100119. DOI:10.1016/j.tru.2022.100119 2022
The mechanistic basis linking cytokine storm to thrombosis in COVID-19 [0.03%]
新冠肺炎中细胞因子风暴导致血栓形成的机制研究
Adam Wolf,Faria Khimani,Braian Yoon et al.
Adam Wolf et al.
It is now well established that infection with SARS-CoV-2 resulting in COVID-19 disease includes a severely symptomatic subset of patients in whom an aggressive and/or dysregulated host immune response leads to cytokine storm syndrome (CSS)...
Acute limb ischemia in COVID-19 patients despite therapeutic anticoagulation: Experience from Africa [0.03%]
COVID-19患者出现急性肢体缺血的个案报道：来自非洲的经验尽管接受了治疗性抗凝治疗
Fikremariam Melkeneh Alemayehu,Dawit Kebede Huluka,Tizazu Kebede Beyene et al.
Fikremariam Melkeneh Alemayehu et al.
Background: Hypercoagulability is a common complication seen in COVID-19 infection. However, arterial thrombosis such as acute limb ischemia (ALI) is far less common. Data on the incidence and nature of arterial thromboem...
Downregulation of thrombomodulin-thrombin-activated protein C pathway as a mechanism for SARS-CoV-2 induced endotheliopathy and microvascular thrombosis [0.03%]
下调血栓调节蛋白-凝血酶-蛋白C通路作为SARS-CoV-2引起的内皮细胞病和微血管血栓形成机制
S Agarwal,C T Cohen,M Zobeck et al.
S Agarwal et al.
There is emerging evidence of microvascular thrombosis and thrombotic microangiopathy (TMA) induced by COVID-19, presumably from endothelial injury. Thrombomodulin (TM) is an endothelial glycoprotein that plays a dual role in maintaining he...
[This corrects the article DOI: 10.1016/j.tru.2020.100031.][This corrects the article DOI: 10.1016/j.tru.2020.100002.][This corrects the article DOI: 10.1016/j.tru.2020.100001.][This corrects the article DOI: 10.1016/j.tru.2020.100007.][Thi...
Published Erratum
Thrombosis update. 2021:2:100044. DOI:10.1016/j.tru.2021.100044 2021
Clinical features, coagulation and inflammatory biomarkers associated with poor in-hospital outcomes in a Honduran population with RT-PCR confirmed COVID-19 [0.03%]
与经RT-PCR确诊的新冠住院预后不良相关的临床特征、凝血和炎症生物标志物（洪都拉斯人口）
David Aguilar-Andino,Andrea N Umaña,César Alas-Pineda et al.
David Aguilar-Andino et al.
Background: SARS-COV-2, in most cases, only generates a mild acute respiratory disease. However, patients with severe disease show an exaggerated response of the immune system, creating a pro-inflammatory state, which cou...
Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis [0.03%]
COVID-19住院期间和出院后的血栓并发症：发生率、危险因素和预防措施
Birgitte Tholin,Hilde Fiskvik,Anders Tveita et al.
Birgitte Tholin et al.
Introduction: The incidence of thromboembolism during COVID-19 and the use of thromboprophylaxis vary greatly between studies. Only a few studies have investigated the rate of thromboembolism post-discharge. This study de...